Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Not yet recruiting

Conditions: Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small Cell Lung
Non-Small Cell Lung Carcinoma
Non Small Cell Lung Cancer
Non Small Cell Lung Carcinoma

Interventions: Drug: azacytidine
Drug: carboplatin
Drug: paclitaxel
Drug: durvalumab
Drug: cisplatin
Drug: gemcitabine
Drug: pemetrexed

First Posted Date: 2024-11-19

Last Posted Date: 2024-12-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT06694454

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Phase 3

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pembrolizumab
Drug: Rilvegostomig
Drug: Carboplatin
Drug: Paclitaxel
Drug: Nab-paclitaxel

First Posted Date: 2024-11-18

Last Posted Date: 2024-12-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 880

Registration Number: NCT06692738

Locations: 🇻🇳
Research Site, Vinh, Vietnam

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

Phase 2

Not yet recruiting

Conditions: Lung Cancer

Interventions: Drug: Pemetrexed 500 mg/m2
Drug: carboplatin
Drug: Sintilimab

First Posted Date: 2024-11-14

Last Posted Date: 2024-11-14

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 30

Registration Number: NCT06688656

Locations: 🇨🇳
241, West Huaihai Road, Shanghai, Shanghai, Shanghai, China

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Phase 3

Not yet recruiting

Conditions: Non Squamous Non Small Cell Lung Cancer

Interventions: Drug: EU-sourced Keytruda®
Drug: MB12 (Proposed Pembrolizumab Biosimilar)
Drug: US-sourced Keytruda®
Drug: Pemetrexed
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2024-11-13

Last Posted Date: 2024-11-13

Lead Sponsor: mAbxience Research S.L.

Target Recruit Count: 726

Registration Number: NCT06687369

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Phase 1

Not yet recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: LM-2417
Drug: Docetaxel
Drug: Toripalimab/Tirelizumab
Drug: Carboplatin
Drug: Niraparib
Drug: Lenvatinib

First Posted Date: 2024-11-11

Last Posted Date: 2024-11-11

Lead Sponsor: LaNova Medicines Limited

Target Recruit Count: 320

Registration Number: NCT06682780

Locations: 🇨🇳
FuDan University Shanghai Cancer Center, Shanghai, Shanghai, China

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Phase 1

Not yet recruiting

Conditions: Unresectable Locally Advanced or Metastatic Solid Tumors

Interventions: Drug: SYHA1813
Drug: Everolimus
Drug: SG001
Drug: Regorafenib
Drug: HB1801
Drug: Carboplatin
Drug: Cisplatin
Drug: Paclitaxel
Drug: Etoposide

First Posted Date: 2024-11-11

Last Posted Date: 2024-11-11

Lead Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd

Target Recruit Count: 380

Registration Number: NCT06682611

Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).

Phase 2

Not yet recruiting

Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Interventions: Drug: Atezolizumab
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2024-10-29

Last Posted Date: 2024-10-29

Lead Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica

Target Recruit Count: 142

Registration Number: NCT06663098

Locations: 🇮🇹
Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano (PN), Italy
🇮🇹
IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy
🇮🇹
IRCCS Azienda Ospedaliero_Universitaria di Bologna, Bologna, Italy

and more 22 locations